Trastuzumab Regimens Offer Long-term Survival Advantages in HER2+ Breast Cancer
Trastuzumab-containing chemotherapy regimens offer superior survival to in HER2-positive early breast cancer.
SABCS 2015
Researchers Continue to Explore HER2 Blockade Strategies
Evidence-based clinical practice has evolved and the search for how best to blockade the HER2 receptor in HER2+ breast cancer continues.
‘Clinically Meaningful’ Response for Presurgical T-DM1 in HER2+ HR+ Early Breast Cancer
Neoadjuvant therapy with the antibody-drug conjugate trastuzumab emtansine (T-DM1) offers clinical response rates in breast cancer.
Fusion Breast Tumor Recurrence Risk, Genomic Instability
Tumors’ RNA fusion transcripts appear to be a promising biomarker of genomic instability and prognostic factors.
Trastuzumab Offers Long-Term Survival Benefits in HER2+ Early Breast Cancer
Trastuzumab after adjuvant chemotherapy for HER2-positive early breast cancer is associated with superior long-term disease-free survival.
Sequential Biopsies, Multi-Level Molecular Profiling Offer Important Insights into Tumor Evolution
Gene copy number, methylation and metabolic changes during neoadjuvant chemotherapy predict treatment outcomes.
Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy
Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.
Mutation Profiles Show How Lobular Carcinoma in Situ Might Evolve Into Invasive Malignancies
Whole exome sequencing analysis reveals considerable mutational heterogeneity among cells within lobular carcinoma in situ (LCIS) lesions.
New Insight Into FGFR1 Gene’s Possible Role in ER+ Breast Cancer Endocrine Resistance
Fibroblast growth factor receptor 1 (FGFR1) gene and ligand co-amplification is associated with endocrine resistance in breast cancer cells.
Recent Clinical Findings for Targeting CDK 4/6 in Breast Cancer
Dr Finn reviewed recent clinical study findings for palbociclib, a first-in-class CDK 4/6-specific inhibitor, abemaciclib, and ribociclib.
Want to read more?
Please login or register first to view this content.
